Literature DB >> 19324442

Image-guided intensity-modulated radiotherapy (IG-IMRT) for biliary adenocarcinomas: Initial clinical results.

Clifton David Fuller1, Nguyen Dinh Dang, Samuel J Wang, Prashant Desai, Mehee Choi, Charles R Thomas, Martin Fuss.   

Abstract

PURPOSE: Biliary tract lesions are comparatively rare neoplasms, with ambiguous indications for radiotherapy. The specific aim of this study was to report the clinical results of a single-institution biliary tract series treated with modern radiotherapeutic techniques, and detail results using both conventional and image-guided intensity-modulated radiation therapy (IG-IMRT). METHODS AND MATERIALS: From 2001 to 2005, 24 patients with primary adenocarcinoma of the biliary tract (gallbladder and extrahepatic bile ducts) were treated by IG-IMRT. To compare outcomes, data from a sequential series of 24 patients treated between 1995 and 2005 with conventional radiotherapy (CRT) techniques were collected as a comparator set. Demographic and treatment parameters were collected. Endpoints analyzed included treatment-related acute toxicity and survival.
RESULTS: Median estimated survival for all patients completing treatment was 13.9 months. A statistically significant higher mean dose was given to patients receiving IG-IMRT compared to CRT, 59 vs. 48Gy. IG-IMRT and CRT cohorts had a median survival of 17.6 and 9.0 months, respectively. Surgical resection was associated with improved survival. Two patients (4%) experienced an RTOG acute toxicity score>2. The most commonly reported GI toxicities (RTOG Grade 2) were nausea or diarrhea requiring oral medication, experienced by 46% of patients.
CONCLUSION: This series presents the first clinical outcomes of biliary tract cancers treated with IG-IMRT. In comparison to a cohort of patients treated by conventional radiation techniques, IG-IMRT was feasible for biliary tract tumors, warranting further investigation in prospective clinical trials.

Entities:  

Mesh:

Year:  2009        PMID: 19324442     DOI: 10.1016/j.radonc.2009.02.015

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  7 in total

1.  Adjuvant chemoradiotherapy for squamous cell carcinoma of gallbladder.

Authors:  Supriya Mallick; Rony Benson; P K Julka; Goura Kishor Rath
Journal:  J Gastrointest Cancer       Date:  2014-12

Review 2.  Radiotherapy and chemotherapy as therapeutic strategies in extrahepatic biliary duct carcinoma.

Authors:  Thomas B Brunner; Cynthia L Eccles
Journal:  Strahlenther Onkol       Date:  2010-11-30       Impact factor: 3.621

Review 3.  External radiotherapy and brachytherapy in the management of extrahepatic and intrahepatic cholangiocarcinoma: available evidence.

Authors:  Puja Sahai; Senthil Kumar
Journal:  Br J Radiol       Date:  2017-05-23       Impact factor: 3.039

4.  Chemoradiation for unresectable gall bladder cancer: time to review historic nihilism?

Authors:  Reena Engineer; Tabassum Wadasadawala; Shaesta Mehta; Umesh Mahantshetty; Nilendu Purandare; Venkatesh Rangarajan; Shyam Kishore Shrivastava
Journal:  J Gastrointest Cancer       Date:  2011-12

5.  Image-guided radiation therapy: Physician's perspectives.

Authors:  T Gupta; C Anand Narayan
Journal:  J Med Phys       Date:  2012-10

6.  Clinical outcomes and toxicity of proton beam therapy for advanced cholangiocarcinoma.

Authors:  Chiyoko Makita; Tatsuya Nakamura; Akinori Takada; Kanako Takayama; Motohisa Suzuki; Yojiro Ishikawa; Yusuke Azami; Takahiro Kato; Iwao Tsukiyama; Yasuhiro Kikuchi; Masato Hareyama; Masao Murakami; Nobukazu Fuwa; Masaharu Hata; Tomio Inoue
Journal:  Radiat Oncol       Date:  2014-01-14       Impact factor: 3.481

Review 7.  Practical review for diagnosis and clinical management of perihilar cholangiocarcinoma.

Authors:  Daniele Dondossola; Michele Ghidini; Francesco Grossi; Giorgio Rossi; Diego Foschi
Journal:  World J Gastroenterol       Date:  2020-07-07       Impact factor: 5.742

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.